TIGIT in particular has proved to be a tricky target for drug developers, and BeiGene's decision comes just a few months after MSD abandoned the development of its anti-TIGIT antibody vibostolimab ...
The EMA has called a temporary halt to a phase 2 trial of Sarepta's Roche-partnered Duchenne muscular dystrophy (DMD) gene ...
The agreement with the GKV-Spitzenverband – the national association of statutory health insurance funds – means that Hemgenix (etranacogene dezaparvovec) can now be reimbursed across Germany's health ...
Vanrafia (atrasentan) is the first drug in the selective endothelin A receptor antagonist (ERA) class to be cleared in the US for IgAN, a disease characterised by the accumulation of antibodies in the ...
Pharmaceuticals are exempt from the cascade of 'Liberation Day' tariffs revealed by President Donald Trump – for now – but ...
Traditional DCTs primarily focus on prospective data collection, adapting interventional research processes to virtual approaches and providing an incomplete picture of patients. This approach offers ...
In recent years, social media has evolved into an essential part of pharma operations, for better or worse. Within the life sciences space, traditional ways of leveraging social media include ...
Recently hired employees of the FDA and CDC look set to be the latest federal employees to be affected by the sweeping job cuts implemented by the Trump administration on agencies overseen by the ...
The results of exclusive research with people seeking health information online in the US, UK and Canada should be a wake-up call for pharma, says Richard Meyer. The results of a recent survey ...
Four more experimental drugs for amyotrophic lateral sclerosis (ALS) have failed to hit the primary endpoint in the phase 2/3 HEALEY ALS basket trial, which is trying to accelerate the search for ...
Having a blueprint for supply chain resiliency is critical, as a mature and robust risk programme enables the right emergency ...
Takeda's Adcetris has become the first drug recommended for routine NHS use as a treatment for previously untreated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback